AMBALAL SARABHAI ENTERPRISES LIMITED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER , 2010

Sr. No;	Perticulars	Three months ended	Corresponding three months in previous year As per Limi	Ywar to date figures for current period ended	Year to gate figures for previous year anded	(Re in Lakhs) Previous accounting year ended Audited
		31-12-2010	31-12-2009	31-12-2010	31-12-2009	31-3-2010
1	(a) Net Sales / Income from operations	648.11	1,420.39	3,549.78	4,131.02	5,765,1
	(b) Other Operating Income	_			1	
	Total Income	848.11	1,420.39	3,549.78	4,131,02	5,768.1
2	Expenditure			"		
	a)(Increase) / decrease in Stock in Trade & Work in Progress	0.58	(23.11)	(27.41)	(95,19)	(18.7
	b) Consumption of Raw Materials	43.70	168.18	376.91	529.80	704,4
	c) Purchase of Traded Goods	464.87	850.17	2,228.73	2,424.85	3,260.9
	d) Employees Cost	356.94	564,00	1,317.10	1,668.18	2,126.1
	e) Depredation	47.50	41.25	124,82	139.50	203.2
	f) Other Expenditure	197.20	293.38	796,53	889,84	1,415.9
	g) Total	1,110.63	1,893.83	4,876,68	5,557.08	7,691,8
3	Profit/(Loss) from operations before other income, interest			.,	_,,,,,,,,	1,051,0
	and exceptional items(1-2)	(464,52)	(473,44)	(1,266.90)	(1,426.06)	(1,926.6
4	Other income	49.22	41.90	95.65	125.01	160.8
5	Profit/(Lose) before interest and exceptional items(3+4)	(415.30)	(431.54)	(1.171.28)	(1,301.06);	(1,796.8
	Interest (Net)	153.37	27.28	408,52	173,61	
7	Profit/(Loss)after interest but before exceptional items(5-6)	(568.67)	(458.80)	(1,579.77)	(1,474,66)	157.8
	Exceptional Items	,,	(400.00)	(1,010.11)	(1,474.00)	(1,923.7
9	Profit/(1088) from ordinary activities before tax(7+8)	(568.67)	(458.80)	44 E70 T70	أ	
	Tax Expenses Provision for Current Tax)	(5502.27)	(400.60)	(1,579.77)	(1,474.66)	(1,923.7
1	Profit/(Loss) from Ordinary Activities after Tax (9-10)	/ran am	-			500.0
	Extraordinary Income/(Expenses) (Net)	(668.67)	(468.80)	(1,579.77)	(1,474.68)	(2,423.7
	Not Profit/(Loss) for the period (11-12)	621.98	(233.99)	639.96	2,666.76	2,634,69
	Pald-up Equity Share Capital	63.29	(692.79)	(939.81)	1,192.10	210.9
- 1	(Face Volue of Re 10 per chare)	7,663.33	7,663.33	7,663.33	7,663.33	7,683,3
	Reserves excluding revaluation reserves		[1		
	Earning Per share(EPS Re)	i i		!	i	(2,480,49
1.		1 1				
ľ	a. Basic and diluted Earnings Per Share before extraordinary Itams (not to be annualised).				1	
		(0.74)	(0.60)	(2.06)	(1.92)	(3.16
	b.Basic and diluted Earnings Per Share after extraordinary items				ŀ	
	(not to be annualised).	0.07	(0.90)	(1.23)	1.56	0.28
	Public Shereholding	i l	Ì	i		
	No of Shares	53314345	53314348	53314345	53314345	5331434
	Percentage of Shareholding	69,57%	69.57%	69.57%	69.57%	69 579
	Promoters & Promoters Group					
- 1	i) Piedged share holding & encumbered	1 1]	ĺ	ļ	
- 1	No of Sheres	NII	NII	Nil	Nii	NII
	Porcentage of Chare (as a percentage of the total share holding or					
	romotors and promoters group)	NII	NII (Nif	Nii j	Nil
. IP	ercentage of Share (as a percentage of the total share					1407
- 1	Sapital of the company)	NII	NII	Nil	Nii	Ner
Þ) Non encumbered		[rad)	Nii
N	lo of Shares	23318951	23318951	22240000		
ĮΡ	ercentage of Share (as a percentage of the total share holding of	100%	100%	23318951	23318951	23318951
	ramoters and promoters group)	1 ,30%	100%	T01096	100%	100%
	ercentage of Share (as a percentage of the total share	20.406			ĺ	
	apital of the company)	30,43%	30.43%	30.43%	30.43%	30.43%



NOTES:

- 1 The Limited Review of the above Unaudited financial Results as required under clause 41 of the listing agreement has been carried out by the statutory auditors.
- 2 The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 06.05.2011
- The Company had no pending investor complaints as on 01-10-10. During current quarter, the Company has received ten complaints which are settled during the quarter. No complaint is lying unresolved at the end of the quarter.
- 4 Provision for taxation if any, will be made at the end of the year.
- The Company has transferred and assigned as a going concern the undertaking and business of Sarabhai Chemicals Bulk Drug Division and Electronics Division comprising of Systronics, Telerad and SERC to Synbiotics Ltd and Systronics (India) Ltd (the subsidiaries of the Company) respectively w.e.f 01.10.2010.
- 6 Extra Ordinary Income is on account of profit on transfer of Sarabhai Chemical Bulk Drug and Electronics undertaking.
- With reference to the qualification in the Auditors Report as on 31.03.10, the Board submits the following explanations:

Impairment of assets: Having regards to the future economic benefits based on company's business plans, company does not expect any impairment in respect of assets.

Previous year's/quarter's figures have been rearranged and regrouped where ever necessary. The above result for the quarter ended does not include figures of Sarabhai Chemicals Bulk Drug Division and Electronics Division, hence the figures of current quarter are not comparable with those of the previous year's quarter ended 31.12.09.

For Ambalal Sarabhai Enterprises Limited

741

Ahmadabad.

06.05-2011

Segment were Boyesta Deserted and Aurit III					(Rs in Lakhs)
Segment wise Revenue, Results and Capital Employed		Corresponding			Previous
	Three months ended	three months In previous year	figures for current period ended	figures for previous year ended	Accounting year ended ended
Particulars					
	31/12/2010	31/12/2009	31/12/2010	31/12/2009	31-03-2010
1.SEGMENT REVENUE net sales /income from				! 	:
segment should be disclosed under this head)	Unaudited	Unaudited	Unaudited	Unaudited	
a.PHARMECEUTICALS	646.11	647.56	1,874.54	1,993.09	2,543;94
b. ELECTRONICS		772.83	1,675.24	2,137.93	3,221.23
TOTAL	646.11	1,420.39	3,549.78	4,131,02	5,765,17
LESS INTER SEGMENT REVENUE	-	-	_		:
NET SALES/INCOME FROM OPERATIONS	646.11	1,420.39	3,549.78	4,131.02	5,765.17
2.SEGMENT RESULTS					:
PROFIT/(LOSS) BEFORE INTEREST & TAX FOR EACH SEGMENT	<u> </u>			,	
a. PHARMACEUTICALS	(464,52)	(546.79)	(1,292.96)	(1,590.94)	(2,038.88)
b. ELECTRONICS	-	73,35	26.06	164.88	112.20
TOTAL	(464.52)	(473.44)	(1,266.90)	(1,426.06)	(1,926,58)
LESS. INTEREST	153.37	27.26	408.52	173.61	157.86
TOTAL	(617.89)	(500.70)	(1,675.42)	(1,599.67)	(2,084.54)
OTHER UNALLOCABLE EXPENDITURE NET OF			(1,575.12)	(1,000.01)	(2,007.54)
UNALLOCABLE INCOME	671.18	(192.09)	735,61	2,791.77	2,795.49
TOTAL PROFIT/(LOSS) BEFORE TAX	53.29	(692.79)	(939.01)	1,192.10	710,95
PROVISION FOR TAXATION	_		_	_	500.00
NET PROFIT/(LOSS)	53.29	(692.79)	(939.81)	1,192,10	210.95
3. CAPITAL EMPLOYED		, , ,			210.00
(Segment Assets-Segment Liabilities)					
1. PHARMACEUTICALS	(901.74)	(1,235.82)	(901.74)	(1,235,82)	162.87
2. ELECTRONICS		2.097.90	(201.74)		
TOTAL CAPITAL EMPLOYED IN SEGMENTS	(901.74)	862.08	(901.74)	2,097.90 862.08	2,105.90 2,268.77
UNALLOCABLE CORPORATE ASSETS			(301.74)	302.06	2,200.17
LESS CORPORATE LIABILITIES	7,901.50	6,641.36	7,901,50	E 844 30	4 440 30
TOTAL	6,999.76	7,503,44	6,999.76	6,641.36 7,503.44	4,416.43 6,685.20



Ahmedabed 06.05. 2011